This book provides a concise overview of recent advances in Pharmacokinetics (PK) and Pharmacodynamics (PD). The pharmacokinetics section covers the state of the art in Physiologically Based Pharmacokinetic (PBPK) modeling (Chapter 1) as well as the assessment of food effect on drug absorption using PBPK modeling (Chapter 2). Chapters 3 and 4 describe the recent development of Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models and their applications to pharmacokinetic data. The pharmacodynamics section focuses on PK/PD modeling. Chapter 5 provides an overview of PK/PD modeling and simulation in clinical practice and studies. Chapter 6 deals with the subject/physiology variability issue encountered in PK/PD studies, while Chapter 7 reviews the influence of clinical pharmacology in the modernization of drug development and regulation. This book is an essential reference for pharmaceutical scientists.

Expert discussion of rapidly expanding field of Pharmacokinetcs and Pharmacodynamics Introduces for the first time the PBFTPK models and the reproducability concept in pharmaceutical sciences Concise overview of advances in PK/PD modeling including COVID-19 information

Autorentext

Panos Macheras is Emeritus Professor (since September 2014) of the Department of Pharmacy, University of Athens.  He is the Founder (1of the Laboratory of Biopharmaceutics and Pharmacokinetics at the University of Athens. He established  the PharmaInformatics Unit of the Research and Innovation Center ATHENA; he is currently the Head of the Unit.Adjunct Professor, Department of Pharmaceutical Sciences, State University of New York (SUNY), Buffalo, USA He received his B. Pharm. and Ph.D degree in Pharmaceutical Chemistry from the University of Athens, Greece.  He also received a Ph.D degree  in Biopharmaceutics-Pharmacokinetics from King's College, University of London, U.K. He has published more than 180 journal articles (more than 6500 citations, h=40) and seven books in the field of Biopharmaceutics-Pharmacokinetics-Pharmacodynamics. His research interests include experimental, theoretical and computational (modeling and simulation) studies on drugdissolution, release, gastrointestinal absorption, protein binding, drug-cyclodextrins interaction, bioequivalence, biopharmaceuitc classification of drugs, pharmacokinetics, fractal and fractional kinetics, applications of fractal concepts in biopharmaceutical systems and nonlinear dynamics. He serves on the Editorial Board of the journals, Pharmaceutical Research, International Journal of Pharmaceutics and European Journal of Pharmaceutical Sciences.

Klappentext

This book provides a concise overview of recent advances in Pharmacokinetics (PK) and Pharmacodynamics (PD). The pharmacokinetics section covers the state of the art in Physiologically Based Pharmacokinetic (PBPK) modeling (Chapter 1) as well as the assessment of food effect on drug absorption using PBPK modeling (Chapter 2). Chapters 3 and 4 describe the recent development of Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models and their applications to pharmacokinetic data. The pharmacodynamics section focuses on PK/PD modeling. Chapter 5 provides an overview of PK/PD modeling and simulation in clinical practice and studies. Chapter 6 deals with the subject/physiology variability issue encountered in PK/PD studies, while Chapter 7 reviews the influence of clinical pharmacology in the modernization of drug development and regulation. This book is an essential reference for pharmaceutical scientists.

Inhalt

Pharmacokinetics .- Chapter 1: Current status in PBPK modeling.- Chapter 2: Physiologically based biopharmaceutics modeling (PBBM) Application on Food Effect Assessment.- Chapter 3: Physiologically based finite time pharmacokinetic (PBFTPK) models: Inception and development.- Chapter 4: Physiologically based finite time pharmacokinetic (PBFTPK) models: Applications.- Pharmacodynamics . - Chapter 5: Pharmacokinetic Pharmacodynamic Modelling and Simulation in Clinical Practice and Studies.- Chapter 6: On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body.- Chapter 7: Impact of Clinical Pharmacology on the Modernization of Drug Development and Regulation.